FrancophonIA/ELRC3.0 huggingface dataset:
English: Polyuria or Pollakiuria j, Urinary tract infection (pyelonephritis and urosepsis have been reported postmarketing)
Croatian: Poliurija ili polakizurija i, infekcija mokraćnog sustava c (pijelonefritis i urosepsa prijavljeni nakon stavljanja lijeka u promet)
English: Studies in animals with canagliflozin have shown reproductive toxicity (see section 5.3).
Croatian: Ispitivanja kanagliflozina na životinjama pokazala su reproduktivnu toksičnost (vidjeti dio 5.3).
English: Adverse reactions in table 1 are based on the pooled analysis of the placebo- and active-controlled studies described above.
Croatian: Nuspojave u tablici 1 temelje se na analizi objedinjenih podataka iz placebom i aktivnim lijekom kontroliranih ispitivanja koja su opisana iznad.
English: • certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II
Croatian: • određene lijekove za liječenje povišenog krvnog tlaka (ACE inhibitori i antagonisti receptora angiotenzina II)
English: Patients with baseline HbA1c > 10% to ≤ 12%
Croatian: Bolesnici s početnom vrijednošću HbA1c > 10% i ≤ 12%
English: Risk factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with eGFR < 60 mL/min/1.73 m
Croatian: Čimbenike koji mogu povećati rizik od laktacidoze (vidjeti dio 4.4) potrebno je provjeriti prije nego što se počne razmatrati uvođenje metformina u bolesnika s eGFR < 60 ml/min/1,73 m
English: The safety of canagliflozin was evaluated in 18,248 patients with type 2 diabetes, including 13,791 patients treated with canagliflozin in combination with metformin.
Croatian: Sigurnost kanagliflozina ocijenjena je u 18 248 bolesnika s dijabetesom tipa 2, uključujući 13 791 bolesnika liječenih kanagliflozinom u kombinaciji s metforminom.
English: Intent-to-treat population using last observation in study.
Croatian: „Intent to treat“ populacija (planirana za liječenje) koristeći posljednje zapažanje u ispitivanju.
English: • Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure,
Croatian: • Akutna ili kronična bolest koja može izazvati hipoksiju tkiva kao što je: srčano ili respiratorno zatajenje, nedavni infarkt miokarda, šok;
English: Haematocrit increase was observed with canagliflozin treatment (see section 4.8); therefore, careful monitoring in patients with already elevated haematocrit is warranted.
Croatian: Tijekom liječenja kanagliflozinom uočeno je povišenje hematokrita (vidjeti dio 4.8); stoga, nalaže se pažljivo nadziranje u bolesnika čiji je hematokrit već povišen.
English: • if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat,talk to a doctor or go to the nearest hospital immediately.
Croatian: • ako iskusite nagli gubitak tjelesne težine, osjećaj mučnine ili povraćanje, bol u trbuhu, prekomjernu žeđ, ubrzano i duboko disanje, smetenost, neuobičajenu pospanost ili umor, zadah slatkog mirisa, slatki ili metalni okus u ustima, ili drugačiji miris mokraće ili znoja, odmah razgovarajte sa svojim liječnikom ili odmah otiđite u najbližu bolnicu.
English: Adults with normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m
Croatian: Odrasli s normalnom funkcijom bubrega (procijenjena brzina glomerularne filtracije [eGFR] ≥ 90 ml/min/1,73 m
English: Table 3 presents adverse reactions by SOC and by frequency category reported in patients who received metformin as monotherapy and that were not observed in patients receiving canagliflozin.
Croatian: Tablica 3 prikazuje nuspojave, prema SOC-u i kategoriji učestalosti, prijavljene u bolesnika koji su primili metformin u monoterapiji, i koje nisu bile zabilježene u bolesnika koji su primili kanagliflozin.
English: Safety data profiles from individual pivotal studies (including studies in moderately renally impaired patients; older patients [≥ 55 years of age to ≤ 80 years of age]; patients with increased CV-risk) were generally consistent with the adverse reactions identified in this table.
Croatian: Profili sigurnosnih podataka iz individualnih pivotalnih ispitivanja (uključujući ispitivanja u bolesnika s blagim oštećenjem bubrega; u starijih bolesnika [≥ 55 godina starosti do ≤ 80 godina starosti]; u bolesnika s povećanim KVrizikom) općenito su u skladu s nuspojavama identificiranima u ovoj tablici.
English: Canagliflozin as initial combination therapy with metformin
Croatian: Kanagliflozin kao inicijalno kombinirano liječenje s metforminom
English: Due to volume depletion, generally small mean decreases in eGFR were seen within the first 6 weeks of treatment initiation with canagliflozin.
Croatian: Zbog deplecije volumena, obično je primijećeno malo smanjenje srednje vrijednosti eGFR unutar prvih 6 tjedana nakon početka liječenja kanagliflozinom.
English: Vokanamet is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise:
Croatian: Vokanamet je indiciran u odraslih s dijabetesom tipa 2, kao dopuna uz dijetu i tjelovježbu:
English: Canagliflozin-induced renal tubule tumours and pheochromocytomas in rats appear to be caused by carbohydrate malabsorption as a consequence of intestinal SGLT1 inhibitory activity of canagliflozin in the gut of rats; mechanistic clinical studies have not demonstrated carbohydrate malabsorption in humans at canagliflozin doses of up to 2-times the maximum recommended clinical dose.
Croatian: Čini se da su tumori bubrežnih tubula i feokromocitomi uzrokovani kanagliflozinom u štakora uzrokovani malapsorpcijom ugljikohidrata kao posljedicom inhibitornog djelovanja kanagliflozina na crijevni SGLT1 u crijevima štakora; mehanistička klinička ispitivanja nisu pokazala malapsorpciju ugljikohidrata u ljudi pri dozama kanagliflozina do 2-puta maksimalne preporučene kliničke doze.
English: • Diabetic pre-coma;
Croatian: • Dijabetička prekoma;
English: In the dedicated cardiovascular study and the larger pooled analysis, discontinuations due to adverse reactions related to volume depletion and serious adverse reactions related to volume depletion were not increased with canagliflozin.
Croatian: U ciljanom kardiovaskularnom ispitivanju i većoj analizi objedinjenih podataka, prekidi liječenja zbog nuspojava povezanih s deplecijom volumena i zbog ozbiljnih nuspojava povezanih s deplecijom volumena, nisu povećani uz kanagliflozin.
English: Mean eGFR returned to baseline after treatment discontinuation suggesting that haemodynamic changes may play a role in these renal function changes.
Croatian: Nakon prekida liječenja srednja vrijednost eGFR vratila se na početnu razinu, što ukazuje na to da promjene hemodinamike možda igraju ulogu u tim promjenama bubrežne funkcije.
English: Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci i kutiji iza oznake „Rok valjanosti“.
English: Canagliflozin
Croatian: Kanagliflozin
English: Adverse reactions listed below are classified according to frequency and system organ class.
Croatian: Niže navedene nuspojave, poredane su prema učestalosti i klasifikaciji organskih sustava.
English: Canagliflozin increased the incidence of testicular Leydig cell tumours in male rats at all doses tested (10, 30, and 100 mg/kg); the lowest dose of 10 mg/kg is approximately 1.5 times the clinical dose of 300 mg based on AUC exposure.
Croatian: Kanagliflozin je povisio incidenciju tumora Leydigovih stanica testisa u mužjaka štakora pri svim ispitanim dozama (10, 30 i 100 mg/kg); najniža doza od 10 mg/kg je približno 1,5 puta kliničke doze od 300 mg na temelju izloženosti prema AUC.
English: Canagliflozin reduced the risk for heart failure requiring hospitalization compared to placebo (HR: 0.67; 95% CI (0.52, 0.87)).
Croatian: Kanagliflozin je smanjio rizik od zatajenja srca koje zahtijeva hospitalizaciju u usporedbi s placebom (HR: 0.67; 95% CI [0,52; 0,87]).
English: The metabolism of canagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyl transferase 1A9 (UGT1A9) and 2B4 (UGT2B4).
Croatian: Metabolizam kanagliflozina odvija se prvenstveno putem glukoronidne konjugacije posredovane UDP glukuronozil transferazom 1A9 (UGT1A9) i 2B4 (UGT2B4).
English: The primary assessment of safety and tolerability was conducted in a pooled analysis (N = 2,313) of four 26-week placebo-controlled clinical studies (monotherapy and add-on therapy with metformin, metformin and a sulphonylurea, and metformin and pioglitazone).
Croatian: Primarna procjena sigurnosti i podnošljivosti provedena analizom objedinjenih podataka (n = 2313) iz četiri 26-tjedna placebom kontrolirana klinička ispitivanja (monoterapija i dodatna terapija s metforminom, metforminom i sulfonilurejom, i metforminom i pioglitazonom).
English: The mean HbA1c at baseline was 8.2% and mean duration of diabetes was 13.5 years.
Croatian: Srednja vrijednost HbA1c na početku ispitivanja iznosila je 8,2%, a srednja vrijednost trajanja dijabetesa 13,5 godina.
English: Lower limb amputations (mainly of the toe and midfoot) especially in patients at high risk for heart disease
Croatian: Amputacije donjih udova (većinom amputacije nožnog prsta i amputacije srednjeg dijela stopala) naročito u bolesnika s visokim rizikom za bolesti srca
English: • Periodic Safety Update Reports (PSURs)
Croatian: • Periodička izvješća o neškodljivosti (PSUR-evi)
English: Table 1: Tabulated list of adverse reactions (MedDRA) from placebo e and active-controlled studies e and from postmarketing experience
Croatian: Tablica 1: Tablični popis nuspojava (MedDRA) iz placebom e i aktivnim lijekom kontroliranih ispitivanja e i iz iskustva nakon stavljanja lijeka u promet
English: Canagliflozin was evaluated in combination with metformin as initial combination therapy in patients with type 2 diabetes failing diet and exercise.
Croatian: Kanagliflozin je bio procijenjen u kombinaciji s metforminom kao inicijalno kombinirano liječenje u bolesnika s dijabetesom tipa 2 kod kojih dijeta i vježbanje nisu bili uspješni.
English: Your doctor will decide when you must stop and when to restart your treatment with Vokanamet.
Croatian: Liječnik će odlučiti kada morate prekinuti i kada ćete nastaviti s liječenjem lijekom Vokanamet.
English: For patients inadequately controlled on maximal tolerated dose of metformin
Croatian: Za bolesnike koji nisu adekvatno regulirani uz maksimalne podnošljive doze metformina
English: N = 4,344
Croatian: Placebo N = 4344
English: For patients switching from separate tablets of canagliflozin and metformin
Croatian: Za bolesnike koji prelaze s pojedinačnih tableta kanagliflozina i metformina
English: The effect of concomitant administration of canagliflozin (a weak P-gp inhibitor) on dabigatran etexilate (a P-gp substrate) has not been studied.
Croatian: Učinak istodobne primjene kanagliflozina (slabi P-gp inhibitor) na dabigatraneteksilat (P-gp supstrat) nije ispitan.
English: • Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell.
Croatian: • Odmah se obratite svom liječniku ako uočite kombinaciju simptoma boli, osjetljivosti (na dodir), crvenila ili oticanja genitalija ili područja između genitalija i anusa s vrućicom ili općim lošim osjećanjem.
English: Related to volume depletion; see section 4.4 and description of adverse reaction (AR) below.
Croatian: Povezano s deplecijom volumena; vidjeti dio 4.4 i opis nuspojave u nastavku.
English: A total of 10,501 patients with type 2 diabetes participated in ten double-blind, controlled clinical efficacy and safety studies conducted to evaluate the effects of canagliflozin on glycaemic control, including 5,151 patients treated with canagliflozin in combination with metformin.
Croatian: Ukupno 10 501 bolesnik s dijabetesom tipa 2 sudjelovao je u deset dvostruko slijepih, kontroliranih ispitivanja kliničke djelotvornosti i sigurnosti koja su provedena radi procjene učinka kanagliflozina na regulaciju glikemije, uključujući 5151 bolesnika liječenog kanagliflozinom u kombinaciji s metforminom.
English: A delayed time to peak plasma concentration was observed for both components (2 hours for canagliflozin and 1 hour for metformin) under fed conditions.
Croatian: U uvjetima sitosti uočeno je zakašnjelo vrijeme do vršnih koncentracija u plazmi za obje komponente (2 sata za kanagliflozin i 1 sat za metformin).
English: Following co-administration of canagliflozin with rifampicin (an inducer of various active transporters and medicinal product-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure (area under the curve, AUC) and peak concentration (Cmax) were observed.
Croatian: Nakon istovremene primjene kanagliflozina s rifampicinom (induktor različitih aktivnih transportera i enzima koji metaboliziraju lijekove), primijećeno je smanjenje sistemske izloženosti kanagliflozinu (površina ispod krivulje, AUC) od 51% i vršne koncentracije (Cmax) od 28%.
English: For patients switching from separate tablets of canagliflozin and metformin, Vokanamet should be initiated at the same total daily dose of canagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Croatian: Za bolesnike koji prelaze s pojedinačnih tableta kanagliflozina i metformina, početna doza uzimanja lijeka Vokanamet mora biti u istim ukupnim dnevnim dozama kanagliflozina i metformina koje se već uzimaju ili u najbližoj prikladnoj terapijskoj dozi metformina.
English: Blood creatinine increased b, o
Croatian: Povišen kreatinin u krvi b,o
English: C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in faeces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively.
Croatian: C]kanagliflozina u zdravih ispitanika, 41,5%; 7,0% i 3,2% primijenjene radioaktivne doze se ponovno našlo u stolici kao kanagliflozin, kao hidroksilirani odnosno O-glukuronidni metabolit.
English: Effects of other medicinal products on canagliflozin
Croatian: Djelovanje drugih lijekova na kanagliflozin
English: The study included 8 subjects with normal renal function (CrCl ≥ 80 mL/min), 8 subjects with mild renal impairment (CrCl 50 mL/min to < 80 mL/min), 8 subjects with moderate renal impairment (CrCl 30 mL/min to < 50 mL/min), and 8 subjects with severe renal impairment (CrCl < 30 mL/min) as well as 8 subjects with ESRD on haemodialysis.
Croatian: Ispitivanje je uključilo 8 ispitanika s normalnom funkcijom bubrega (CrCl ≥ 80 ml/min), 8 ispitanika s blagim oštećenjem bubrega (CrCl 50 ml/min do < 80 ml/min), 8 ispitanika s umjerenim oštećenjem bubrega (CrCl 30 ml/min do < 50 ml/min), 8 ispitanika s teškim oštećenjem bubrega (CrCl < 30 ml/min), kao i 8 ispitanika u završnom stadiju bubrežne bolesti na hemodijalizi.
English: Use in patients at risk for adverse reactions related to volume depletion
Croatian: Primjena u bolesnika s rizikom pojave nuspojava povezanih s deplecijom volumena
English: Persistent renal findings in juvenile rats can most likely be attributed to reduced ability of the developing rat kidney to handle canagliflozin-increased urine volumes, as functional maturation of the rat kidney continues through 6 weeks of age.
Croatian: Trajni bubrežni nalazi u mladunčadi štakora najvjerojatnije se mogu pripisati smanjenoj sposobnosti bubrega u razvoju štakora da podnese kanagliflozinom izazvan porast volumena mokraće, budući da funkcionalno sazrijevanje bubrega u štakora traje tijekom 6 tjedna starosti.
English: Stop taking Vokanamet and talk to a doctor or go to the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Croatian: Prestanite uzimati Vokanamet i odmah se obratite liječniku ili otiđite u najbližu bolnicu ako osjetite neke od simptoma laktacidoze, jer to stanje može dovesti do kome.
English: Multipack: 180 (3 packs of 60) film-coated tablets
Croatian: Višestruko pakiranje: 180 (3 pakiranja od 60) filmom obloženih tableta
English: When canagliflozin/metformin was administered at 60/300 mg/kg/day (exposure levels 11 and 13 times the clinical exposure for canagliflozin and metformin, respectively, at 300/2000 mg doses), the effects were more pronounced compared to metformin alone.
Croatian: Kada je kanagliflozin/metformin bio primijenjen u dozi od 60/300 mg/kg/dan (razine izloženosti 11 odnosno 13 puta veće od kliničkih izloženosti za kanagliflozin i metformin, pri dozama od 300/2000 mg), učinci su bili izraženiji u usporedbi sa samim metforminom.
English: Multipack containing 180 (3 x 60) film-coated tablets.
Croatian: Višestruko pakiranje koje sadrži 180 (3 x 60) filmom obloženih tableta.
English: Vokanamet is contraindicated in patients with severe renal failure (eGFR < 30 mL/min) (see section 4.3).
Croatian: Vokanamet je kontraindiciran u bolesnika s teškim zatajenjem bubrega (eGFR < 30 ml/min) (vidjeti dio 4.3).
English: BOTTLE LABEL
Croatian: NALJEPNICA ZA BOCU
English: From a starting value of RTG of approximately 13 mmol/L, maximal suppression of 24-hour mean RTG was seen with the 300 mg daily dose to approximately 4 mmol/L to 5 mmol/L in patients with type 2 diabetes in phase 1 studies, suggesting a low risk for treatment-induced hypoglycaemia.
Croatian: Od početne vrijednosti RTG od oko 13 mmol/l, maksimalna supresija 24-satne srednje vrijednosti RTG primijećena je s dnevnom dozom od 300 mg na oko 4 mmol/l do 5 mmol/l u bolesnika s dijabetesom tipa 2 u ispitivanjima faze 1, što upućuje na nizak rizik hipoglikemije uzrokovane terapijom.
English: Frequency categories are based on information available from the metformin Summary of Product Characteristics.
Croatian: Kategorije učestalosti temeljene su na informacijama koje su dostupne u sažetku opisa svojstava lijeka za metformin.
English: Vokanamet is contraindicated in patients with hepatic impairment due to the active substance metformin (see sections 4.3 and 5.2).
Croatian: Vokanamet je kontraindiciran u bolesnika s oštećenjem jetrene funkcije zbog djelatne tvari metformina (vidjeti dijelove 4.3 i 5.2).
English: In three studies conducted in special populations (elderly patients, patients with an eGFR of 30 mL/min/1.73 m2 to < 50 mL/min/1.73 m2 and patients with or at high risk for cardiovascular disease), canagliflozin was added to patients' current stable diabetes treatments (diet, monotherapy, or combination therapy).
Croatian: U tri ispitivanja provedena s posebnim populacijama (stariji bolesnici, bolesnici s eGFR od 30 ml/min/1,73 m2 do < 50 ml/min/1,73 m2 i bolesnici s kardiovaskularnom bolešću ili s visokim rizikom za kardiovaskularne bolesti), kanagliflozin je bolesnicima dodan uz trenutno stabilno liječenje dijabetesa (dijeta, monoterapija ili kombinirano liječenje).
English: The dose of glucose-lowering therapy with Vokanamet should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability, using the recommended daily dose of 100 mg or 300 mg canagliflozin and not exceeding the maximum recommended daily dose of metformin orally.
Croatian: Doza lijeka Vokanamet u terapiji snižavanja šećera mora se odrediti za svakog bolesnika ponaosob na temelju dosadašnje terapije, učinkovitosti i podnošljivosti, uz primjenu preporučene dnevne doze od 100 mg ili 300 mg kanagliflozina i bez prekoračenja maksimalne preporučene dnevne doze metformina, peroralno.
English: Table 2: Integrated analysis of amputations in CANVAS and CANVAS-R Placebo
Croatian: Tablica 2: Analiza objedinjenih podataka o amputacijama iz ispitivanja CANVAS i CANVAS-R
English: Possible signs of low blood sugar are: blurred vision tingling lips trembling, sweating, looking pale a change in mood or feeling anxious or confused.
Croatian: Mogući znakovi niskog šećera u krvi su: zamagljenje vida trnci usana drhtanje, znojenje, bljedilo promjene raspoloženja, osjećaj tjeskobe ili smetenosti.
English: Polyuria or pollakiuria includes the terms polyuria, pollakiuria, micturition urgency, nocturia, and urine output increased.
Croatian: Poliurija ili polakizurija uključuju termine poliurija, polakizurija, žurno mokrenje, nokturija i povećano stvaranje mokraće.
English: Balanitis or balanoposthitis includes the terms balanitis, balanoposthitis, balanitis candida, and genital infection fungal.
Croatian: Balanitis ili balanopostitis uključuju termine balanitis, balanopostitis, balanitis uzrokovan kandidom i genitalna gljivična infekcija.
English: Bahía de Pollensa, 11
Croatian: Mundipharma Pharmaceuticals, S.L. Bahía de Pollensa, 11
English: Based on postmarketing experience with canagliflozin.
Croatian: Temeljeno na iskustvu nakon stavljanja kanagliflozina u promet.
English: See section 3, “Taking this medicine”.
Croatian: “Uzimanje ovog lijeka”.
English: • if you have signs of a genital yeast infection such as irritation, itching, unusual discharge or odour
Croatian: • ako imate znakove gljivične spolne infekcije poput iritacije, svrbeži, neuobičajenog iscjetka ili neugodnog mirisa.
English: There have been no clinical efficacy studies conducted with Vokanamet; however, bioequivalence of Vokanamet to canagliflozin and metformin co-administered as individual tablets was demonstrated in healthy subjects.
Croatian: Nisu provedena klinička ispitivanja djelotvornosti s lijekom Vokanamet; međutim, u zdravih ispitanika pokazana je bioekvivalencija lijeka Vokanamet u odnosu na kanagliflozin i metformin koji su istodobno primijenjeni u pojedinačnim tabletama.
English: A total of 10,134 patients were treated (4,327 in CANVAS and 5,807 in CANVAS-R; total of 4,344 randomly assigned to placebo and 5,790 to canagliflozin) and exposed for a mean of 149 weeks (exposed for a mean of 223 weeks in CANVAS and 94 weeks in CANVAS-R).
Croatian: Liječena su ukupno 10 134 bolesnika (4327 u sklopu ispitivanja CANVAS i 5807 u sklopu ispitivanja CANVAS-R; ukupno 4344 bolesnika randomizirana su za placebo, a njih 5790 za kanagliflozin), koja su bila izložena lijeku tijekom srednjeg razdoblja od 149 tjedana (srednja vrijednost izloženosti iznosila je 223 tjedna u ispitivanju CANVAS i 94 tjedna u ispitivanju CANVAS-R).
English: • and delay of intestinal glucose absorption.
Croatian: • odgađajući intestinalnu apsorpciju glukoze.
English: In addition, canagliflozin reduced progression of albuminuria 25.8% versus placebo 29.2% (HR: 0.73; 95% CI: 0.67, 0.79) in patients with baseline normo- or micro-albuminuria.
Croatian: Dodatno, kanagliflozin je smanjio progresiju albuminurije, iznosila je 25,8% za kanagliflozin naspram 29,2% za placebo (HR: 0,73; 95% CI: 0,67, 0,79) u bolesnika s normo- ili mikro-albuminurijom na početku ispitivanja.
English: • rash or red skin - this may be itchy and include raised bumps, oozing fluid or blisters.
Croatian: • osip ili crvena koža - koji može svrbiti i biti izbočen, uz curenje tekućine ili mjehuriće.
English: Mean percent increases from baseline for canagliflozin 100 mg and 300 mg versus placebo, respectively, were total cholesterol 3.4% and 5.2% versus 0.9%; HDL-cholesterol 9.4% and 10.3% versus 4.0%; LDL-cholesterol 5.7% and 9.3% versus 1.3%; non-HDL-cholesterol 2.2% and 4.4% versus 0.7%; triglycerides 2.4% and 0.0% versus 7.6%.
Croatian: Srednji postotak porasta u odnosu na početnu vrijednost za kanagliflozin od 100 mg odnosno 300 mg naspram placeba, bio je za ukupni kolesterol 3,4% i 5,2% naspram 0,9%; HDL kolesterol 9,4% i 10,3% naspram 4,0%; LDL kolesterol 5,7% i 9,3% naspram 1,3%; ne HDL kolesterol 2,2% i 4,4% naspram 0,7%; trigliceride 2,4% i 0,0% naspram 7,6%.
English: 300 mg exhibited mean improvements in percent change in body weight relative to placebo of -1.8% and -2.0%, respectively.
Croatian: 100 mg i 300 mg pokazala su srednju vrijednost poboljšanja u postotku promjene tjelesne težine u odnosu na placebo od -1,8% odnosno -2,0%.